Observational studyMedicine2025
Effect of metformin on free testosterone level in male diabetic patients: A comparative study.
Observational study in Medicine, 2025. The graph read 1 number from its abstract, feeding 1 cell of the map, but none could be read as for or against, so it casts no vote. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
But. free testosterone rise in non-metformin group(M = 2.63,SD = 1.07) was significantly higher (mean difference = .80,95% CI) than metformin group (M = 1.82,SD = .99,t = 4.76, P < .001).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Other glucose-lowering×inflammation & biomarkers
No readable resultOpen on the map →What to test next →No other readable study in this cell yet. This paper is the evidence.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
When we consider the treatment of polycystic ovary syndrome (PCOS), one of our treatment options is metformin, which reduces free testosterone levels in PCOS patients. We were interested to know what happens to the free testosterone levels of male type 2 diabetes mellitus (T2DM) patients when we use metformin. The effect of metformin on testosterone level, fertility, and sexual activity in males has been issues of interest to researchers. This study was conducted to observe the effect of metformin on free testosterone levels in male T2DM patients. One hundred fifty male patients (mean age, 40-46 years; SD, 1.2), newly diagnosed with T2DM and drug-naïve, were enrolled. Initially, the baseline-free testosterone level was measured. Then, 75 of them were given metformin, and 75 of them were treated with other antidiabetics. After treatment for 30 days, the free testosterone level was measured again. In both groups, the mean value of free testosterone change in 1 month was calculated. Then, a comparison between the mean change in the 2 groups was done. Baseline-free testosterone of metformin (mean = 7.9, SD = 2.2) and non-metformin (mean = 8.1, SD = 1.9) groups were compared, and no significant difference was seen between them (P = .264). After 30 days of treatment, there was an increased level of free testosterone in both groups (mean metformin = 9.75, non-metformin = 10.77). But. free testosterone rise in non-metformin group(M = 2.63,SD = 1.07) was significantly higher (mean difference = .80,95% CI) than metformin group (M = 1.82,SD = .99,t = 4.76, P < .001). Metformin is inferior to other antidiabetic medications in raising free testosterone levels. Larger multicenter studies are further warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.